Drugs / MAb425
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00589706 | Jan 1985 → Dec 2012 | malignant glioma | Drexel University College of Medicine | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT01317888 | Jan 2010 → Jan 2014 | anaplastic astrocytoma, glioblastoma | Drexel University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mAb 425 | “MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.” NCT01317888 ↗4“anti-epidermal growth factor receptor 425 murine monoclonal antibody ((125)I-mAb 425)” PMID 20345222 ↗ Aug 2010 “MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection” NCT00589706 ↗ |
| Known as | Anti-EGFr-425 | “Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFr-425) Monoclonal Antibody Radiolabeled With 1-125” NCT01317888 ↗ |
| Modality | Monoclonal antibody | “Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFr-425) Monoclonal Antibody” NCT01317888 ↗ |
| Route | Intravenous | “3 weekly intravenous injections” PMID 20345222 ↗ Aug 2010 |
| Target | EGFR | “anti-epidermal growth factor receptor 425” NCT00589706 ↗ |